Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lipocine

3.35
+0.05001.52%
Post-market: 3.450.1000+2.99%19:27 EDT
Volume:13.32K
Turnover:44.74K
Market Cap:17.92M
PE:-4.38
High:3.42
Open:3.36
Low:3.22
Close:3.30
Loading ...

Lipocine Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Mar

Lipocine FY24 Sales $11.198M Beat $10.321M Estimate

Benzinga
·
13 Mar

Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Dow Jones
·
13 Mar

Lipocine Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
03 Mar

Lipocine receives updated regulatory guidance on LPCN 1154

TIPRANKS
·
06 Feb

Lipocine Inc - FDA Requires Efficacy and Safety Study for Lpcn 1154 Nda Submission

THOMSON REUTERS
·
06 Feb

Lipocine Receives Updated Regulatory Guidance on Lpcn 1154

THOMSON REUTERS
·
06 Feb

Lipocine Inc - Plans Phase 3 Safety and Efficacy Study for Lpcn 1154

THOMSON REUTERS
·
06 Feb

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

PR Newswire
·
06 Feb

Lipocine Says LPCN 1148 Gets FDA Fast Track Label

MT Newswires Live
·
18 Dec 2024

FDA Grants Fast Track Designation to Lipocine for Lpcn 1148 as a Treatment for Sarcopenia in Patients With Decompensated Cirrhosis

THOMSON REUTERS
·
17 Dec 2024

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

PR Newswire
·
17 Dec 2024

BRIEF-Lipocine Announces Publication And Discussion Of LPCN 1148 Manuscript At The Liver Meeting 2024 Editor's Cut Session

Reuters
·
18 Nov 2024

Lipocine announces publication, discussion of LPCN 1148

TIPRANKS
·
18 Nov 2024

Lipocine Announces Publication and Discussion of Lpcn 1148 Manuscript at the Liver Meeting 2024 Editor's Cut Session

THOMSON REUTERS
·
18 Nov 2024

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

PR Newswire
·
18 Nov 2024